Skip to main content

Advertisement

SpringerLink
Log in

Asparaginase in the treatment of non-ALL hematologic malignancies

  • Review Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Asparaginases are among the most effective agents against acute lymphoblastic leukemia (ALL) and are Food and Drug Administration-approved for the treatment of pediatric and adult ALL. However, the efficacy of these drugs for the treatment of other hematologic malignancies particularly acute myeloid leukemia is not well established. The mechanism of action of asparaginases has thought to be related to a swift and sustained reduction in serum l-asparagine, which is required for rapid proliferation of metabolically demanding leukemic cells. However, asparagine depletion alone appears not to be sufficient for effective cytotoxic activity of asparaginase against leukemia cells, because glutamine can rescue asparagine-deprived cells by regeneration of asparagine via a transamidation chemical reaction. For this reason, glutamine reduction is also necessary for full anti-leukemic activity of asparaginase. Indeed, both Escherichia coli and Erwinia chrysanthemi asparaginases possess glutaminase enzymatic activity, and their administrations have shown to reduce serum glutamine level by deamidating glutamine to glutamate and ammonia. Emerging data have provided evidence that several types of neoplastic cells require glutamine for the synthesis of proteins, nucleic acids, and lipids. This fundamental role of glutamine and its metabolic pathways for growth and proliferation of individual malignant cells may identify a special group of patients whose solid or hematologic neoplasms may benefit significantly from interruption of glutamine metabolism. To this end, asparaginase products deserve a second look particularly in non-ALL malignant blood disorders. Here, we review mechanisms of anti-tumor activity of asparaginase focusing on importance of glutamine reduction, pharmacology of asparaginase products, in vitro activities as well as clinical experience of incorporating asparaginase in therapeutic regimens for non-ALL hematologic malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kidd JG (1953) Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. II. Studies on the nature of the active serum constituent: histological mechanism of the regression: tests for effects of guinea pig serum on lymphoma cells in vitro: discussion. J Exp Med 98(6):583–606

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Broome JD (1961) Evidence that the L-asparaginase activity in guinea pig serum is responsible for antilymphoma effects. Nature 191:1114–1115

    Article  CAS  Google Scholar 

  3. Yellin TO, Wriston JC Jr (1966) Antagonism of purified asparaginase from guinea pig serum toward lymphoma. Science 151(3713):998–999

    Article  CAS  PubMed  Google Scholar 

  4. Dolowy WC, Henson D, Cornet J, Sellin H (1966) Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer 19(12):1813–1819

    Google Scholar 

  5. Wade HE, Elsworth R, Herbert D, Keppie J, Sargeant K (1968) A new L-asparaginase with antitumour activity? Lancet 2(7571):776–777

    Article  CAS  PubMed  Google Scholar 

  6. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH (2011) L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 117(2):238–249

    Google Scholar 

  7. Dhavala P, Papageorgiou AC (2009) Structure of Helicobacter pylori L-asparaginase at 1.4 Å resolution. Acta Crystallogr D Biol Crystallogr 65(Pt 12):1253–1261

    Google Scholar 

  8. Soru E, Teodorescu M, Zaharia O, Szabados J, Rudescu K (1972) L-Asparaginase from the BCG strain of Mycobacterium bovis. I. Purification and in vitro immunosuppressive properties. Can J Biochem 50(11):1149–1157

    Article  CAS  PubMed  Google Scholar 

  9. DeJong PJ (1972) L-Asparaginase production by Streptomyces griseus. Appl Microbiol 23(6):1163–1164

    CAS  PubMed Central  PubMed  Google Scholar 

  10. Jones P, Kristiansen T, Einarsson M (1973) Purification and properties of L-asparaginase from Acinetobacter calcoaceticus. Biochem Biophys Acta 327:146

    Google Scholar 

  11. Lee B, Yang HJ, Henry GM, Seymour JP, Chibata I (1975) Crystallographic studies on L-asparaginase from Proteus vulgaris. II. Symmetry and location of the tetrameric molecule. J Biol Chem 250(16):6228–6231

    CAS  PubMed  Google Scholar 

  12. Whelan HA, Wriston JC Jr (1974) Purification and properties of L-asparaginase from Serratia marcescens. Biochim Biophys Acta 365(1):212–222

    Article  CAS  PubMed  Google Scholar 

  13. Abuchowski A, Kafkewitz D, Davis FF (1979) A rapid purification procedure for L-asparaginase from Vibrio succinogenes. Prep Biochem 9(3):205–211

    Google Scholar 

  14. Kavitha A, Vijayalakshmi M (2012) A study on L-asparaginase of Nocardia levis MK-VL_113. Sci World J. 2012:160434

  15. Lubkowski J, Palm GJ, Gilliland GL, Derst C, Rohm KH, Wlodawer A (1996) Crystal structure and amino acid sequence of Wolinella succinogenes L-asparaginase. Eur J Biochem 241(1):201–207

    Article  CAS  PubMed  Google Scholar 

  16. Lubkowski J, Wlodawer A, Ammon HL, Copeland TD, Swain AL (1994) Structural characterization of pseudomonas 7A glutaminase-asparaginase. Biochemistry 33(34):10257–10265

    Article  CAS  PubMed  Google Scholar 

  17. Ortlund E, Lacount MW, Lewinski K, Lebioda L (2000) Reactions of Pseudomonas 7A glutaminase-asparaginase with diazo analogues of glutamine and asparagine result in unexpected covalent inhibitions and suggests an unusual catalytic triad Thr-Tyr-Glu. Biochemistry 39(6):1199–1204

    Article  CAS  PubMed  Google Scholar 

  18. Amylon MD, Shuster J, Pullen J et al (1999) Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13(3):335–342

    Article  CAS  PubMed  Google Scholar 

  19. FDA Label for Asparaginase: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/101063s5169lbl.pdf

  20. FDA Label for Erwinaze: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125359lbl.pdf

  21. Abuchowski A, Kazo GM, Verhoest CR Jr et al (1984) Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 7(2):175–186

    CAS  PubMed  Google Scholar 

  22. Capizzi RL, Bertino JR, Skeel RT et al (1971) L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 74(6):893–901

    Article  CAS  PubMed  Google Scholar 

  23. Ho DH, Whitecar JP Jr, Luce JK, Frei E 3rd (1970) L-asparagine requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow. Cancer Res 30(2):466–472

    CAS  PubMed  Google Scholar 

  24. Kamisaki Y, Wada H, Yagura T, Matsushima A, Inada Y (1981) Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. J Pharmacol Exp Ther 216(2):410–414

    CAS  PubMed  Google Scholar 

  25. Wada H, Imamura I, Sako M et al (1990) Antitumor enzyme: polyethylene glycol-modified asparaginase. Ann N Y Acad Sci 613:95–108

    Article  CAS  PubMed  Google Scholar 

  26. Patel S, Benfield P (1996) Pegasparaginase (polyethylene glycol L-asparaginase). Clin Immunother 5:492–496

    Article  Google Scholar 

  27. Ettinger LJ, Kurtzberg J, Voute PA, Jurgens H, Halpern SL (1995) An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 75(5):1176–1181

    Article  CAS  PubMed  Google Scholar 

  28. Cedar H, Schwartz JH (1967) Localization of the two asparaginases in anaerobically grown E. coli. J Biol Chem 247:3753–3755

    Google Scholar 

  29. Covini D, Tardito S, Bussolati O et al (2012) Expanding targets for a metabolic therapy of cancer: L-asparaginase. Recent Pat Anticancer Drug Discov 7(1):4–13

    Article  CAS  PubMed  Google Scholar 

  30. Schwartz JH, Reeves JY, Broome JD (1966) Two L-asparaginases from E. coli and their action against tumors. Proc Natl Acad Sci USA. 56(5):1516–1519

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Cedar H, Schwartz JH (1968) Production of L-asparaginase II by Escherichia coli. J Bacteriol 96(6):2043–2048

    CAS  PubMed Central  PubMed  Google Scholar 

  32. Willis RC, Woolfolk CA (1974) Asparagine utilization in Escherichia coli. J Bacteriol 118(1):231–241

    CAS  PubMed Central  PubMed  Google Scholar 

  33. Casale TD, Sollitti P, Chesney RH (1983) Cytoplasmic L-asparaginase: isolation of a defective strain and mapping of ans A. J Bacteriol 154:513–515

    PubMed Central  PubMed  Google Scholar 

  34. Jennings MP, Beacham IR (1990) Analysis of the Escherichia coli gene encoding L-asparaginase II, ansB, and its regulation by cyclic AMP receptor and FNR proteins. J Bacteriol 172(3):1491–1498

    CAS  PubMed Central  PubMed  Google Scholar 

  35. Pui CH, Boyett JM, Relling MV et al (1999) Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol 17(3):818–824

    CAS  PubMed  Google Scholar 

  36. Pui CH, Campana D, Evans WE (2001) Childhood acute lymphoblastic leukaemia—current status and future perspectives. Lancet Oncol 2(10):597–607

    Article  CAS  PubMed  Google Scholar 

  37. Kiriyama Y, Kubota M, Takimoto T et al (1989) Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase. Leukemia 3(4):294–297

    CAS  PubMed  Google Scholar 

  38. Prager MD, Bachynsky N (1968) Asparagine synthetase in asparaginase resistant and susceptible mouse lymphomas. Biochem Biophys Res Commun 31(1):43–47

    Article  CAS  PubMed  Google Scholar 

  39. Avramis VI, Panosyan EH (2005) Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 44(4):367–393

    Article  CAS  PubMed  Google Scholar 

  40. Panosyan EH, Grigoryan RS, Avramis IA et al (2004) Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer research 24(2C):1121–1125

    CAS  PubMed  Google Scholar 

  41. Souba WW (1993) Glutamine and cancer. Ann Surg 218(6):715–728

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Cooney DA, Capizzi RL, Handschumacher RE (1970) Evaluation of l-asparagine metabolism in animals and man. Cancer Res 30(4):929–935

    CAS  PubMed  Google Scholar 

  43. Mardashev SR, Nikolaev A, Kozlov EA, Petrii OP (1975) Purification of microbial asparaginases by the aid of affinity chromatography. Biokhimiia 40(1):78–82

    CAS  PubMed  Google Scholar 

  44. Kamble VP, Rao RS, Borkar PS, Khobragade CN, Dawane BS (2006) Purification of L-asparaginase from a bacteria Erwinia carotovora and effect of a dihydropyrimidine derivative on some of its kinetic parameters. Indian J Biochem Biophys 43(6):391–394

    CAS  PubMed  Google Scholar 

  45. Ho PP, Milikin EB, Bobbitt JL et al (1970) Crystalline L-asparaginase from Escherichia coli B. I. Purification and chemical characterization. J Biol Chem 245(14):3708–3715

    CAS  PubMed  Google Scholar 

  46. Derst C, Henseling J, Rohm KH (2000) Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248. Protein Sci 9(10):2009–2017

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Moola ZB, Scawen MD, Atkinson T, Nicholls DJ (1994) Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes. Biochem J 302(Pt 3):921–927

    CAS  PubMed Central  PubMed  Google Scholar 

  48. Kotzia GA, Labrou NE (2007) L-Asparaginase from Erwinia chrysanthemi 3937: cloning, expression and characterization. J Biotechnol 127(4):657–669

    Article  CAS  PubMed  Google Scholar 

  49. Avramis VI (2011) Asparaginases: a successful class of drugs against leukemias and lymphomas. J Pediatr Hematol Oncol 33(8):573–579

    Article  PubMed  Google Scholar 

  50. Jarrar M, Gaynon PS, Periclou AP et al (2006) Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children’s Oncology Group study (CCG-1941). Pediatr Blood Cancer 47(2):141–146

    Article  PubMed  Google Scholar 

  51. Avramis VI, Sencer S, Periclou AP et al (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 99(6):1986–1994

    Article  CAS  PubMed  Google Scholar 

  52. Fine BM, Kaspers GJ, Ho M, Loonen AH, Boxer LM (2005) A genome-wide view of the in vitro response to L-asparaginase in acute lymphoblastic leukemia. Cancer Res 65(1):291–299

    CAS  PubMed  Google Scholar 

  53. Shan J, Lopez MC, Baker HV, Kilberg MS (2010) Expression profiling after activation of the amino acid deprivation response in HepG2 human hepatoma cells. Physiol Genomics 41(3):315–327

    Google Scholar 

  54. Reinert RB, Oberle LM, Wek SA et al (2006) Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem 281(42):31222–31233

    Article  CAS  PubMed  Google Scholar 

  55. Willems L, Jacque N, Jacquel A et al (2013) Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 122(20):3521–3532

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Offman MN, Krol M, Patel N et al (2011) Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. Blood 117(5):1614–1621

    Article  CAS  PubMed  Google Scholar 

  57. Ollenschlager G, Roth E, Linkesch W, Jansen S, Simmel A, Modder B (1988) Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest 18(5):512–516

    Article  CAS  PubMed  Google Scholar 

  58. Panosyan EH, Seibel NL, Martin-Aragon S et al (2004) Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: children’s Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 26(4):217–226

    Article  PubMed  Google Scholar 

  59. Douer D, Yampolsky H, Cohen LJ et al (2007) Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 109(7):2744–2750

    CAS  PubMed  Google Scholar 

  60. Pui CH (2009) Toward a total cure for acute lymphoblastic leukemia. J Clin Oncol 27(31):5121–5123

    Article  PubMed  Google Scholar 

  61. Schwartz MK, Lash ED, Oettgen HF, Tomato FA (1970) L-asparaginase activity in plasma and other biological fluids. Cancer 25(2):244–252

    Article  CAS  PubMed  Google Scholar 

  62. Dibenedetto SP, Di Cataldo A, Ragusa R, Meli C, Lo Nigro L (1995) Levels of l-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia. J Clin Oncol 13(2):339–344

    CAS  PubMed  Google Scholar 

  63. Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG (1981) L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 41(11 Pt 1):4554–4558

    CAS  PubMed  Google Scholar 

  64. Woo MH, Hak LJ, Storm MC et al (1999) Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. J Clin Oncol 17(5):1568–1573

    CAS  PubMed  Google Scholar 

  65. Ho DH, Yap HY, Brown N et al (1981) Clinical pharmacology of intramuscularly administered L-asparaginase. J Clin Pharmacol 21(2):72–78

    Article  CAS  PubMed  Google Scholar 

  66. Haskell CM, Canellos GP, Leventhal BG et al (1969) L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 281(19):1028–1034

    Article  CAS  PubMed  Google Scholar 

  67. Kurtzberg J, Asselin B, Poplack D (1994) PEG L-asparaginase (PEG-ASP) pharmacology in pediatric patients with acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol 13:114

    Google Scholar 

  68. Leventhal BG, Henderson ES (1971) Therapy of acute leukemia with drug combinations which include asparaginase. Cancer 28(4):825–829

    Article  CAS  PubMed  Google Scholar 

  69. Capizzi RL (1993) Asparaginase revisited. Leuk Lymphoma 10(Suppl):147–150

    Article  PubMed  Google Scholar 

  70. Goldberg AI, Cooney DA, Glynn JP, Homan ER, Gaston MR, Milman HA (1973) The effects of immunization to L-asparaginase on antitumor and enzymatic activity. Cancer Res 33(2):256–261

    CAS  PubMed  Google Scholar 

  71. Agrawal V, Woo J, Borthakur G, Kantarjian H, Frankel A (2013) Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia. Protein Pept Lett 20(4):392–402

    Article  CAS  PubMed  Google Scholar 

  72. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ (1993) Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 11(9):1780–1786

    CAS  PubMed  Google Scholar 

  73. Duval M, Suciu S, Ferster A et al (2002) Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children’s Leukemia Group phase 3 trial. Blood 99(8):2734–2739

    Article  CAS  PubMed  Google Scholar 

  74. Moghrabi A, Levy DE, Asselin B et al (2007) Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109(3):896–904

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  75. Vieira Pinheiro JP, Ahlke E, Nowak-Gottl U et al (1999) Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol 104(2):313–320

    Article  CAS  PubMed  Google Scholar 

  76. Boos J, Werber G, Ahlke E et al (1996) Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 32A(9):1544–1550

    Article  CAS  PubMed  Google Scholar 

  77. Clarkson B, Krakoff I, Burchenal J et al (1970) Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer 25(2):279–305

    Article  CAS  PubMed  Google Scholar 

  78. Crowther D (1971) L-asparaginase and human malignant disease. Nature 229(5281):168–171

    Article  CAS  PubMed  Google Scholar 

  79. Tardito S, Uggeri J, Bozzetti C et al (2007) The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase. Cancer Chemother Pharmacol 60(5):751–758

    Article  CAS  PubMed  Google Scholar 

  80. Lorenzi PL, Llamas J, Gunsior M et al (2008) Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther 7(10):3123–3128

    Article  CAS  PubMed  Google Scholar 

  81. Lorenzi PL, Reinhold WC, Rudelius M et al (2006) Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 5(11):2613–2623

    Article  CAS  PubMed  Google Scholar 

  82. Tardito S, Chiu M, Uggeri J et al (2011) L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of beta-catenin-mutated human hepatocellular carcinoma cells. Curr Cancer Drug Targets 11(8):929–943

    Article  CAS  PubMed  Google Scholar 

  83. Zhang B, Dong LW, Tan YX et al (2013) Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br J Cancer 109(1):14–23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Scotti C, Sommi P, Pasquetto MV et al (2010) Cell-cycle inhibition by Helicobacter pylori L-asparaginase. PLoS ONE 5(11):e13892

    Article  PubMed Central  PubMed  Google Scholar 

  85. Cappelletti D, Chiarelli LR, Pasquetto MV, Stivala S, Valentini G, Scotti C (2008) Helicobacter pylori L-asparaginase: a promising chemotherapeutic agent. Biochem Biophys Res Commun 377:1222–1226

    Article  CAS  PubMed  Google Scholar 

  86. Capizzi RL, Cheng Y (1981) Therapy of neoplasia with asparaginase. In: Holcenberg JS, Robert J (eds) Enzymes as drugs. Wiley, New York, pp 1–24

    Google Scholar 

  87. Winston J, Yellin TO (1973) L-asparaginase: a review. Adv Enzymol 39:185–248

    Google Scholar 

  88. Hill JM, Roberts J, Loeb E, Khan A, MacLellan A, Hill RW (1967) L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA 202(9):882–888

    Article  CAS  PubMed  Google Scholar 

  89. Okada S, Hongo T, Yamada S et al (2003) In vitro efficacy of L-asparaginase in childhood acute myeloid leukemia. Br J Haematol 123(5):802–809

    Article  CAS  PubMed  Google Scholar 

  90. Zwaan CM, Kaspers GJ, Pieters R et al (2000) Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 96(8):2879–2886

    CAS  PubMed  Google Scholar 

  91. Jun SA, Sepiashvili L, Kislinger T, Minden MD (2011) Investigating the potential use of L-asparaginase in myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 118:3641

    Google Scholar 

  92. Takahashi H, Koh K, Kato M, Kishimoto H, Oguma E, Hanada R (2012) Acute myeloid leukemia with mediastinal myeloid sarcoma refractory to acute myeloid leukemia therapy but responsive to L-asparaginase. Int J Hematol 96(1):136–140

    Article  CAS  PubMed  Google Scholar 

  93. Narta UK, Kanwar SS, Azmi W (2007) Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol 61(3):208–221

    Article  PubMed  Google Scholar 

  94. Perel Y, Auvrignon A, Leblanc T et al (2002) Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucamie Aique Myeloide Enfant. J Clin Oncol 20(12):2774–2782

    Article  PubMed  Google Scholar 

  95. Wrobel G, Dobaczewski G, Kazanowska B et al (2000) Adverse reactions associated with the use of L-asparaginase during therapy of patients with nB non-Hodgkin’s lymphoma. Report of the Polish Paediatric Leukaemia/Lymphoma Study Group. Med Wieku Rozwoj 4(1 Suppl 2):67–72

    CAS  PubMed  Google Scholar 

  96. Kobrinsky NL, Sposto R, Shah NR et al (2001) Outcomes of treatment of children and adolescents with recurrent non-Hodgkin’s lymphoma and Hodgkin’s disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: children’s Cancer Group Study CCG-5912. J Clin Oncol 19(9):2390–2396

    CAS  PubMed  Google Scholar 

  97. Agrawal NR, Bukowski RM, Rybicki LA, Kurtzberg J, Cohen LJ, Hussein MA (2003) A phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma. Cancer 98(1):94–99

    Article  CAS  PubMed  Google Scholar 

  98. Ishida F, Kwong YL (2010) Diagnosis and management of natural killer-cell malignancies. Expert Rev Hematol 3(5):593–602

    Article  CAS  PubMed  Google Scholar 

  99. Jaccard A, Gachard N, Marin B et al (2011) Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 117(6):1834–1839

    Article  CAS  PubMed  Google Scholar 

  100. Matsumoto Y, Nomura K, Kanda-Akano Y et al (2003) Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma 44(5):879–882

    Article  CAS  PubMed  Google Scholar 

  101. Schwartz S, Morgenstern B, Capizzi RL (1982) Schedule dependent synergy and antagonism between high dose cytosine arabinoside and L-asparaginase in the L5178Y murine leukemia. Cancer Res 42:2191

    CAS  PubMed  Google Scholar 

  102. Capizzi RL, Poole M, Cooper MR et al (1984) Treatment of poor risk acute leukemia with sequential high dose ARA-C and asparaginase. Blood 63(3):694–700

    CAS  PubMed  Google Scholar 

  103. Capizzi RL, Davis R, Powell B et al (1988) Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia- a cancer and Leukemia group B study. J Clin Oncol 6(3):499–508

    CAS  PubMed  Google Scholar 

  104. Wells RJ, Woods WG, Lampkin BC et al (1993) Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Children’s Cancer Group. J Clin Oncol 11(3):538–545

    CAS  PubMed  Google Scholar 

  105. Horikoshi A, Takei K, Iriyama N et al (2009) Effect of L-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (M0) associated with non-Hodgkin Lymphoma. Acta Haematol 122:54–57

    Article  PubMed  Google Scholar 

  106. Fujita H, Iguchi M, Tachibana T et al (2006) Remission induction treatment for 6 patients of Jehovah’s witnesses with de novo acute leukemia. Blood (ASH Annual Meeting Abstracts). 108:4553

    Google Scholar 

  107. Buaboonnam J, Cao X, Pauley JL et al (2013) Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. Pediatr Blood Cancer 60(7):1161–1164

    Article  PubMed  PubMed Central  Google Scholar 

  108. Ahmed T, Holwerda S, Isom S, Lyerly S, Ellis LR, Manuel M, Dralle S, Dmitriy B, Klepin HD, Powell BL, Pardee T (2013) High dose cytarabine, mitoxantrone and L-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) In the elderly. Blood (ASH Annual Meeting Abstracts). 122:2700

  109. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712–1723

    Article  CAS  PubMed  Google Scholar 

  110. Howlader N, Noone AM, Krapcho M et al (2012) SEER Cancer Stat Rev, 1975–2010. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2010/. Based on November 2012 SEER data submission, posted to the SEER web site, April 2013. Accessed 19 Jan 2014

  111. Emadi A, Jun SA, Tsukamoto T, Fathi AT, Minden MD, Dang CV (2013) Inhibition of glutaminase selectively suppresses the growth of primary AML cells with IDH mutations. Exp Hematol. doi:10.1016/j.exphem.2013.12.001

Download references

Conflict of interest

The authors report no relevant conflict of interest.

Author information

Authors and Affiliations

  1. Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, 22 S. Greene Street, S9D04C, Baltimore, MD, 21201, USA

    Ashkan Emadi, Hania Zokaee & Edward A. Sausville

Authors
  1. Ashkan Emadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hania Zokaee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward A. Sausville
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashkan Emadi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Emadi, A., Zokaee, H. & Sausville, E.A. Asparaginase in the treatment of non-ALL hematologic malignancies. Cancer Chemother Pharmacol 73, 875–883 (2014). https://doi.org/10.1007/s00280-014-2402-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-014-2402-3

Keywords

Search

Navigation